No Data
Beijing Leadman Biochemistry (300289.SZ): Medical AI transformation is currently one of the industry development trends closely watched by the company.
Gelonghui November 8th | Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the medical AI transformation is currently one of the closely watched industry development trends by the company.
Beijing Leadman Biochemistry (300289.SZ): The patented application scenarios of microfluidic fluorescence immunoassay chip technology are in the field of clinical immunological analysis.
Gelonghui November 1st | Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the patented application scenarios of the microfluidic fluorescence immunoassay chip technology obtained by the company are in the field of immunological analysis in clinical testing.
Leadman: Third quarter report 2024
Beijing Leadman Biochemistry (300289.SZ): The net income in the first three quarters was 1.0716 million yuan, a year-on-year decrease of 95.49%.
On October 25, Gelonhui announced its third quarter report. In the first three quarters of 2024, beijing leadman biochemistry achieved revenue of 0.282 billion yuan, a decrease of 17.15% year-on-year; net income attributable to shareholders of the listed company was 1.0716 million yuan, a decrease of 95.49% year-on-year; net loss after deducting non-recurring gains and losses was 6.5087 million yuan, a decrease of 130.05% year-on-year; basic earnings per share were 0.0020 yuan/share.
Beijing Leadman Biochemistry (300289.SZ) released its performance for the first three quarters, with a net income of 1.0716 million yuan, a year-on-year decrease of 95.49%.
Beijing Leadman Biochemistry (300289.SZ) released the third quarter report for 2024, with revenue in the first three quarters at 2.8...
beijing leadman biochemistry (300289.SZ): currently has not established cooperation with Sino Biological.
On October 25th, Gelunhui reported that beijing leadman biochemistry (stock code: 300289.SZ) stated on the investor interaction platform that the company has not established a partnership with Sino Biological.
No Data
